Cytek Biosciences (CTKB) Capital Expenditures (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Capital Expenditures data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 54.06% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $588000.0 (down 20.33% YoY), and the FY2025 full-year result was $129000.0, down 27.12% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.3 million, up from $44000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $4.6 million in Q4 2023 and bottomed at -$2.3 million in Q3 2025.
• The 5-year median for Capital Expenditures is $288000.0 (2024), against an average of $461705.9.
• The widest annual swing landed in 2022, when Capital Expenditures surged 872.57%; it then tumbled 2404.55% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $1.4 million in 2022, then soared by 236.69% to $4.6 million in 2023, then sank by 98.29% to $78000.0 in 2024, then plunged by 43.59% to $44000.0 in 2025, then jumped by 2872.73% to $1.3 million in 2026.
• The last three Capital Expenditures figures came in at $1.3 million (Q1 2026), $44000.0 (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.

Peer Comparison